A Single Center, Randomized, Parallel Safety Study To Evaluate The Immunogenicity Of A Novel Glucagon Formulation Compared To Commercially Available Glucagon Administered By Intramuscular Injection In Adults With Type 1 OR Type 2 Diabetes
Phase of Trial: Phase III
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Glucagon (Primary) ; Glucagon (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors AMG Medical
- 22 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinialTrials.gov record.
- 19 Nov 2014 Planned End Date changed from 1 Apr 2014 to 1 Dec 2014, according to ClinialTrials.gov record.
- 19 Nov 2014 Status changed from recruiting to active, no longer recruiting, according to ClinialTrials.gov record.